Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-02-12
2008-09-30
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S233000, C548S235000, C546S209000, C540S602000, C540S603000, C514S326000, C514S217090
Reexamination Certificate
active
07429607
ABSTRACT:
The present invention relates to compounds of formula I:wherein one of R1and R4is selected from the group consisting of H, and optionally substituted C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyl-C1-4alkyl, and phenyl-C1-4alkyl; and the other of R1and R4is an optionally substituted C9-14aryl group; R2and R3are either:(i) independently selected from H, R, R′, SO2R, C(═O)R, (CH2)nNR5R6, where n is from 1 to 4 and R5and R6are independently selected from H and R, where R is optionally substituted C1-4alkyl, and R′ is optionally substituted phenyl-C1-4alkyl, or(ii) together with the nitrogen atom to which they are attached, form an optionally substituted C5-7heterocyclic group; and their use as pharmaceuticals, in particular for treating conditions alleviated by the antagonism of a 5-HT2Breceptor.
REFERENCES:
patent: 5679678 (1997-10-01), Binder et al.
patent: 5952331 (1999-09-01), Berger et al.
patent: 5958934 (1999-09-01), Berger et al.
patent: 6177452 (2001-01-01), Momose et al.
patent: WO 95/24200 (1995-08-01), None
patent: WO 96/24351 (1996-09-01), None
patent: WO 97/44326 (1997-11-01), None
patent: WO 00/23444 (2000-04-01), None
patent: WO 01/08668 (2001-02-01), None
patent: WO 01/14372 (2001-03-01), None
Bansal, E., et al.,Ind. J. Chem., 39B, 357-362 (2000).
Berge, et al., 1977,J. Pharm. Sci., 66, 1-19.
Cockerill, A.F., et al.,Synthesis, 1976, 591-593.
Cooper, C., et al.,J. Med. Chem., 33, 1246-1252 (1990).
Crank, G. and Foulis, J.,J. Med, Chem., 14(11), 1075-1077 (1971).
Crank, G. and Kahn., H.R.,Aust. J. Chem., 38, 447-458 (1985).
Gompper, R., and Christmann, O.,Chem. Ber.92, 1944-1949 (1959).
Hoyer, et al.,Pharm. Rev., 46, 157-203 (1994).
Martin and Humphrey,Neuropharm., 33, 261-273 (1994).
Launay, J.M., et al.,Nature Medicine, 8(10), 1129-1135 (2002).
Nath, J., et al.,Ind. J. Chem., 20B, 606-607 (1981).
Pattanayak, B., et al.,J. Ind. Chem. Soc., 16B, 1030-1032 (1978).
Pattanayak, B., et al.,J. Ind. Chem. Soc., 55, 264-267 (1978).
Newton et al, Microwaves—A Short Path from the Cook's Kitchen to the Chemist's Laboratory, Global Outsourcing Review, vol. 5, No. 2, May 2003, pp. 1-5.
Bansal et al., “Synthesis and anti-inflammatory activity of 1-acetyl-5-substitute daryl-3-(β-aminonaphthyl)-2-pyrazolines and β-(substituted aminoethyl) amidonaphthalenes”, Eur. J. Med. Chem. 36 (2001) 81-92.
Chemical Abstract 2000-100698 & Bansal et al., Oriental Journal of Chemistry, 15(3), 489-494.
Belstein, Registry No. 985793, XP-002239724, (Nov. 29, 1998).
Belstein, Registry No. 1213623, SP-002239725, (Nov. 29, 1988).
Chemical Abstracts, vol. 66, 1967, p. 8886.
Molina et al., Synthesis (1993) (1), 54-6 (Abstract).
Aley Amanda
Archer Janet Ann
Borman Richard Anthony
Clark Kenneth Lyle
Coleman Robert Alexander
Asterand UK Limited
Nixon & Vanderhye P.C.
Wang Shengjun
LandOfFree
5-HT 2B receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5-HT 2B receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-HT 2B receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3982577